Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, today announced the presentation of preclinical data supporting .HEAL-101, its in vivo base editing product candidate targeting APOC3 for severe hypertriglyceridemia (sHTG), at the Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), being held October 27-30, 2026, in Hamburg, Germany.
Covered in this story
Call it yourself
No calls on $CLLS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Cellectis →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.